CIK 0000873303
- Large accelerated filer
Sarepta Therapeutics, Inc.
Sign in to watch- Ticker
- SRPT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 930797222
- Phone
- +1 617-274-4000
- Business address
- 215 FIRST STREET, SUITE 415, CAMBRIDGE, MA, 02142
- Former names
- Sarepta Therapeutics, Inc., AVI BIOPHARMA INC, ANTIVIRALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-01 | Arif Bilal Chief Tech Ops Officer | Grant or award | +6,000 | 28,836 | ||
| 2024-03-01 | Arif Bilal Chief Tech Ops Officer | Sale | −1,543 | $128.58 | $198K | 27,293 |
| 2024-03-01 | Arif Bilal Chief Tech Ops Officer | Sale | −457 | $129.71 | $59K | 26,836 |
| 2024-03-01 | Arif Bilal Chief Tech Ops Officer | Shares withheld for taxes | −114 | $126.19 | $14K | 26,722 |
| 2024-03-01 | Arif Bilal Chief Tech Ops Officer | Grant or award · Stock Option (right to buy) | −12,500 | 12,500 | ||
| 2024-03-01 | Estepan Ian Michael Chief Financial Officer | Shares withheld for taxes | −365 | $126.19 | $46K | 34,314 |
| 2024-03-01 | Estepan Ian Michael Chief Financial Officer | Grant or award | +6,000 | 40,314 | ||
| 2024-03-01 | Estepan Ian Michael Chief Financial Officer | Sale | −1,200 | $128.30 | $154K | 39,114 |
| 2024-03-01 | Estepan Ian Michael Chief Financial Officer | Grant or award · Stock Option (right to buy) | −12,500 | 12,500 | ||
| 2023-12-01 | Arif Bilal Chief Tech Ops Officer | Shares withheld for taxes | −3,682 | $80.34 | $296K | 22,886 |
| 2023-11-17 | Rodino-Klapac Louise Head of R&D, CSO | Shares withheld for taxes | −4,508 | $82.98 | $374K | 65,751 |
| 2023-11-03 | Barry Richard Director | Purchase | +10,000 | $78.81 | $788K | 10,000 |
| 2023-11-03 | Barry Richard Director | Purchase | +40,000 | $78.81 | $3.2M | 140,000 |
| 2023-11-03 | INGRAM DOUGLAS S President & CEO | Purchase | +10,081 | $78.57 | $792K | 375,163 |
| 2023-11-03 | INGRAM DOUGLAS S President & CEO | Purchase | +11,060 | $79.70 | $881K | 386,223 |
| 2023-11-03 | INGRAM DOUGLAS S President & CEO | Purchase | +3,884 | $80.33 | $312K | 390,107 |
| 2023-11-03 | INGRAM DOUGLAS S President & CEO | Purchase | +200 | $81.26 | $16K | 390,307 |
| 2023-11-03 | BEHRENS M KATHLEEN Director | Exercise or conversion | +15,000 | $29.03 | $435K | 174,993 |
| 2023-11-03 | BEHRENS M KATHLEEN Director | Exercise or conversion · Stock Option (Right to Buy) | −15,000 | 0 | ||
| 2023-08-14 | Chambers Michael Andrew Director | Purchase | +5,947 | $109.19 | $649K | 242,964 |
Page 14 of 22 · 424 trades